natgillin/translations-raw huggingface dataset:
Calculate the Colour Intensity of the material as follows: 
Izračuna se intenzitet boje materijala kako slijedi:
The leveling spacer according to the preceding claims, characterized in that said base (11) with the spacing protrusions (12) and the threaded stem (13) with the wings (17) are made monolithically of plastic material. 
Umetak za niveliranje prema prethodnim zahtjevima, naznačen time, da je navedena osnova (11) s izbočinama za razmak (12) te s navojnim deblom (13) s krilima (17), izrađena monolitno od plastičnog materijala.
The syringe of claim 9, wherein the barrel of the syringe contains an injectable suspension comprising leuprolide acetate. 
Štrcaljka u skladu s patentnim zahtjevom 9, naznačena time što cilindar štrcaljke sadrži injekcijsku suspenziju koja sadrži leuprolid-acetat.
determining a number of actual counts of the respective first allele based on the sequencing of the plurality of nucleic acid molecules from the biological sample; and determining the fetal genome is heterozygous for the respective first and second allele and the maternal genome is homozygous for the respective second allele when the number of actual counts is less than the cutoff value. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se određivanje prve skupine lokusa sastoji u tome što: za svakog od lokusa iz prve skupine: određivanje očinskog genoma je homozigotno za odgovarajući prvi alel; i određivanje majčinskog genoma je homozigotno za odgovarajući drugi alel.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use according to claim 1, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is/are formulated for oral, parenteral, subcutaneous, intravenous, intramuscular, nasal, topical or rectal administration. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koja/koje se upotrebljava(ju) u liječenju i/ili prevenciji autoimunog hepatitisa prema zahtjevu 1, naznačena/e time, da se nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, formulira(ju) za oralnu, parenteralnu, subkutanu, intravenoznu, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu.
The method of claim 6(iv), wherein said clinical variables are selected from the group consisting of tumor size, node status, histologic grade, estrogen hormone receptor status, progesterone hormone receptor status, HER-2 levels, and tumor ploidy. 
Postupak u skladu s patentnim zahtjevom 6(1v), naznačen time što navedene kliničke varijable se bira iz skupine koju čine veličina tumora, status čvora, histološki stupanj, status receptora hormona estrogena, status receptora hormona progesterona, razine HER-2, te ploidnost tumora.
Polyacrylamide provides an excellent template and matrix for cell growth. 
Poliakrilamid osigurava izvanrednu podlogu i matricu za rast stanica.
The kit of clause46, wherein the first mobilizable detector comprises an Fc-binding molecule conjugated to a first detectable entity, and wherein the Fc-binding molecule is protein A and/or protein G. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što prvi detektor sadrži molekulu koja se veže na Fc, konjugiranu s prvim detektibilnim entitetom, te što je molekula koja se veže na Fc protein A i/ili protein G.
a 5' wing segment consisting of five linked nucleosides; and a 3' wing segment consisting of five linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; wherein each internucleoside linkage is a phosphorothioate linkage and wherein each cytosine is a 5-methylcytosine. 
pri čemu modificiran oligonukleotid obuhvaća: segment razmaka koji se sastoji od deset vezanih deoksinukleozida; 5 segment,krila" koji se sastoji od pet vezanih nukleozida; i 3" segment,,krila" koji se sastoji od pet vezanih nukleozida; pri čemu se segment razmaka nalazi između 5 segmenta,krila" 1 3* segmenta,krila", pri čemu svaki 10 nukleozid iz svakog segmenta,,krila" obuhvaća 2'-O-metoksietil šećer; pri čemu svaka internukleozidna veza je fosforotioatna veza i pri čemu svaki citozin je 5-metilcitozin.
Preferably the heterocyclic group is e.g. pyridyl or morpholino. 
Povoljno, heterociklička skupina je, na primjer piridil ili morfolin.
a disorder of mood; or 
poremećaj raspoloženja; ili -
ii) removing from the resulting tetrazole of formula (I), wherein F: comprises a protected reactive group, the protecting group 
(ii) uklanjanje zaštine skupine s rezultirajućeg tetrazola formule (1), gdje F sadrži zaštićenu reaktivnu skupinu.
In a more specific embodiment, the second tharapeutic agent is selected from ritonavir, efavirenz, didanosine, tenofovir disoproxil, nelfinavir mesilate, amprenavir, raltegravir, saquinavir, lopinavir, nevirapine, emtricitabine, abacavir, lamivudine, zidovudine maraviroc, stavudine, darunavir, fosamprenavir, vicriviroc, pharmaceutically acceptable salts of any of the foregoing, and combinations thereof. 
Kompozicija prema zahtjevu 10, gdje se drugo terapeutsko sredstvo bira od ritonavira, efavirenca, = didanozina, tenofovir-disoproksila, nelfinavir mesilata, amprenavira, kalij-raltegravira, sakvinavira, = lopinavira, - nevirapina, emtricitabina, abakavira, lamivudina, zidovudina, maraviroka, stavudina, darunavira, fosamprenavira, vicrivirica, farmaceutski prihvatljive soli bilo kojeg od gore navedenih ili njihove kombinacije.
a crankshaft (108), rotating about a crankshaft axis (110) of the engine; 
koljenasto vratilo (108) koje se okreće oko osi koljenastog vratila (110);
Preferably the tumour marker is a tumour antigen selected from carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2). 
Konjugat prema zahtjevu 1 ili 2, naznačen time da je tumorski marker tumorski antigen, i pri čemu je tumorski antigen po potrebi karcinoembrijski antigen (CEA).
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-iljamid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
represents an optionally substituted C1-6 alkylene group, an optionally substituted C2-6 alkenylene group or an optionally substituted C2-6 alkynylene group; 
predstavlja po izboru supstituiranu C1-6 alkilensku skupinu, prema potrebi supstituiranu C2-6 alkenilen skupinu ili po izboru supstituiranu C2-6 alkinilensku skupinu;
is CH2Z, with Z a group of the formula 
R4 je CH2Z, gdje je Z skupina formule
0-5% by weight of additives; and 0-4% by weight of solvents and/or water. 
(TCB), 0-5% po masi aditiva, te 0-4% po masi otapala i/ili vode.
The method of claim 7, wherein the neurodegenerative disease is a motor neuron disease selected from the group consisting of progressive bulbar palsy, pseudobulbar palsy, primary lateral sclerosis (PLS), progressive muscular atrophy, spinal muscular atrophy (SMA), post-polio syndrome (PPS)-Marie-Tooth disease, Guillan-Barré syndrome, and adrenomyeloneuropathy (AMN). 
Spoj, ili smjesa spojeva, namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je neurodegenerativna bolest Alzheimerova bolest, Huntingtonova koreja, Parkinsonova bolest, amiotrofna lateralna skleroza (ALS), degenerativne ataksije, multipla skleroza, višesistemna atrofija, leukodistrofija, spinalna muskularna atrofija (SMA), primarna lateralna skleroza (PLS), progresivna bulbarna paraliza ili psedobulbarna paraliza.
a peptide linker comprising SEQ ID NO:8 Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser, wherein the N-terminal glycine of the peptide linker is directly fused to the C-terminal glycine residue of the GLP-1 analog and the C-terminal serine of the peptide linker is directly fused to N-terminal alanine of the Fc portion. 
(c) peptidnu spojnicu koja sadrži SEQ ID NO:8 Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser, gdje je N-terminalni glicin peptidne spojnice izravno fuzioniran s C-terminalnim glicinskim ostatkom GLP-1 analoga, a C-terminalni serin peptidne spojnice je izravno fuzioniran s N-terminalnim alaninom Fc dijela.
The process of paras 1, 2 or 3, further comprising combining the waste polymer and the functional filler with a peroxide-containing additive and/or an antioxidant to form a recycled polymer. 
Postupak u skladu s patentnim zahtjevima 1, 2 ili 3, naznačen time što se dodatno sastoji u miješanju otpadnog polimera s funkcionalnim punilom s aditivom koji sadrži peroksid i/ili antioksidans kako bi se dobilo reciklirani polimer.
the compound of formula IIBb/tenofovir disoproxil fumarate/GS-9131/emtricitabine, 
Farmaceutski sastav prema patentnom zahtjevu 7, koji sadrži kombinaciju kombinacije spoja formule IIBb/tenofovir dizoproksil fumarat/darunavir.
The composition for use according to claim 9, wherein the additional drug for treating Alzheimer's disease is selected from the group consisting of donepezil, galantamine, memantine, rivastigmine and tacrine. 
Sastav za uporabu prema zahtjevu 9, naznačen time, da je dodatni lijek za liječenje Alzheimerove bolesti, odabran iz skupine koju čine donepezil, galantamin, memantin, Tivastigmin 1 takrin.
The method of claim 99, wherein said biguanide or sulphonylurea is selected from the group consisting of tolbutamide, chlorpropamide, acetohexamide, tolazamide, glibenclamide, glipizide or any combination thereof. 
(i) navedeni bigvanid ili sulfonilurea je tolbutamid, klorpropamid, acetoheksamid, tolazamid, glibenklamid, glipizid ili bilo koja njihova kombinacija;
The method of claim 13, wherein the lubricant and antiadherent is selected from the group consisting of stearates such as magnesium stearate, calcium stearate and sodium stearate; stearic acid; talc waxes; stearowet; boric acid; sodium chloride; DL-leucine; carbowax 4000; carbowax 6000; sodium oleate; sodium benzoate; sodium acetate; sodium lauryl sulfate; and magnesium lauryl sulfate. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što su lubrikant i antiadheziv izabrani iz grupe koju čine stearati kao što su magnezij stearat, kalcij stearat i natrij stearat; stearinska kiselina; talk voskovi; stearovet; borna kiselina; natrij klorid; DL-leucin; carbovax 4000; carbovax 6000; natrij oleat; natrij benzoat; natrij acetat; natrij lauril sulfat; i magnezij lauril sulfat.
Further, PEG may decrease antigenicity and potentially enhances the overall rigidity of the linker. 
Nadalje, PEG može smanjiti antigenost i potencijalno povećati sveukupnu krutost veznika.
The method of claim 4, wherein the pinanediol boronic ester is obtained by a step selected from coupling a bis-trimethylsilyl (TMS)2 amine derivative with RaCOOH, or reacting a bis-trimethylsilyl (TMS)2 amine derivative with RaCOCl, wherein the bis-trimethylsilyl amine derivative has the structure of formula (XI): 
Postupak prema patentnom zahtjevu 3, naznačen time, da se pinandiol ester boronske kiseline dobiva putem koraka koji je odabran od spajanja bis- trimetilsilil (TMS)2 derivata amina s RaCOOH, ili reakcije bis-trimetilsilil (TMS)2 derivata amina s RaCOCl, pri čemu bis-trimetilsilil derivat amina ima strukturu formule (XI):
The method of claim 21, wherein the melt is shaped into a film or a foam before being allowed to solidify. 
Postupak temeljem zahtjeva 10, naznačen time da je talina u obliku filma ili pjene prije nego se pusti da očvrsne.
A compound according to claim 1, wherein R1 is pyridinyl substituted with R3, R4 and R5. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je R1 piridinil supstituiran s R3, R4 i R5.
The method of any one of claims 1-2, 9-12, 14-20, 21-31, the molecule for use of any one of claims 3-8, 10-12, or 24-31, or the implantable device of claim 13 or 24-31, further comprising a moiety that increases solubility of the molecule. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 2, 9 do 12, 14 do 20, 21 do 31, molekule za uporabu u skladu s bilo kojim od patentnih zahtjeva 3 do 8, 10 do 12 ili 24 do 31, ili uređaj za implantiranje u skladu s patentnim zahtjevom 13 ili 24 do 31, naznačen time, da nadalje sadržava dio koji povećava topljivost molekule.
detecting the formation of the immunologic complex; 
(c) detektiranja formiranja imunološkog kompleksa;
The beverage dispensing assembly according to claim 1, wherein the sealing means for hermetically sealing the collapsible container to the base part is provided between the outer wall of the base unit and the base part. The beverage dispensing assembly according to claim 7, wherein resilient support means are provided for temporarily spacing the container and base unit from the base part. 
Sklop za točenje pića prema zahtjevu 7 ili 8, naznačen time, da je sredstvo za hermetičko brtvljenje sklopivog spremnika (2) prema osnovnom dijelu (5) predviđeno između vanjske stijenke (16) osnovne jedinice (3) i osnovnog dijela 5.
The sail propulsion system according to claim 1, wherein the points of connection of the two lateral shrouds to the deck are secured such that the two lateral shrouds on which the two mainsails (RS, RD) are rove also support the mast (A). 
Porivni sustav za jedrenje prema zahtjevu 1 ili 2, naznačen time što su dva glavna jedra (RS, RD) pričvršćena na istim bočnim priponama (S) koje podupiru jarbol (A).
n is an integer in the range of from 1 to 6; 
W' je C=CH; n je cijeli broj u rasponu od 1 do 6;
a number of injection units corresponding to a multiple of the cylinder number in the engine, and which are connected with each their dosing cylinder with a dosing piston; a supply line for cylinder lubricating oil; 
"niz jedimica za ubrizgavanje (251) koje odgovaraju višekratniku broja cilindara u motoru i kojo su povezane svaka sa svojim dozirnim cilindrom s dozirnim klipom (21), dovodna hnija za mazivo ulje za cilindar;
From day on, cells were diluted with a fixed dilution ratio of 1/4. 
Od 20. dana nadalje, stanice su razrjeđivane pri stalnom omjeru razrjeđenja od 1/4. dan
The compound of para 1, wherein ring D is 
Spojevi prema patentnom zahtjevu 1, pri čemu prsten D je
R25 at each occurrence is independently selected from H, F, Cl, Br, C1-C6 alkyl, C1-C6 and alkyloxy; 
R* uvijek kada se pojavljuje je neovisno odabran od H, F, Cl, Br, C,-C; alkila, i C,-C; alkiloksi; xje1,2,31li 4; naznačen time da sadrži korake:
The method of claim 1, wherein the antisense oligonucleotide is chemically linked to a polyethylene glycol chain. 
Antisens oligonukleotid u skladu sa zahtjevom 16, naznačen time što navedeni antisens oligonukleotid je kemijski vezan na polietilen-glikolski lanac.
This fuel plug was inserted into a 17 mm long aluminum foil lined tube so that 3 mm of the fuel element was inside the tube. 
Ovaj gorivi čep umetnut je u 17 mm dugu cijev obloženu sa aluminijskom folijom tako da je 3 mm gorivog elementa bilo unutar cijevi.
a hydroxy-containing polymer which is a combination of polyvinyl alcohol and at least one member selected from the group consisting of starch, modified starch and a sugar; 
(a) sadržan hidroksi-polimer, koji je kombinacija polivinil-alkohola i najmanje jednog, iz grupe izdvojenog, koji se sastoji od škroba, modificiranog škroba 1 šećera,
A head according to claim. 1, characterized in that it comprises means for guiding said belt along said feeding path; said guide means comprising said unwinding means and idle rollers distributed along said path and having radial support surfaces for the longitudinal edges of said belt. 
Glava u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da obuhvaća sredstva za vođenje navedene trake duž navedene staze za punjenje; navedena sredstva za vođenje sadržavaju navedena sredstva za odmotavanje i slobodne valjke koji su raspoređeni duž navedene staze i imaju radijalne podloge za uzdužne rubove navedene trake.
at least one antiepileptic selected from the group consisting of pregabalin and gabapentin, with the proviso that (1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol of formula (I') is not a slow release tapentadol. 
(b) barem jedan antiepileptik odabran iz skupine koja se sastoji od pregabalina i gabapentina, uz uvjet da (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol formule (I) nije tapentadol sa sporim otpuštanjem.
The pharmaceutical composition of claim 10, wherein the wetting agent is sodium lauryl sulfate. 
Farmaceutska kompozicija prema patentnom zahtjevu 10, naznačena time što je sredstvo za vlaženje natrijev lauril sulfat.
A multi-armed polymer prodrug of embodiment 41, wherein said prodrug, when evaluated in a suitable animal model for solid tumor-type cancers and administered in a therapeutically effective amount, is effective to suppress tumor growth to an extent that is at least 2 times that observed for the unmodified anticancer agent when similarly administered over a time course of 60 days. 
Višestruko razgranati polimerni prolijek iz patentnog zahtjeva 2, pri čemu je navedeni prolijek, procijenjen na odgovarajućem životinjskom modelu za karcinome čvrstog tipa i primijenjen u terapijski učinkovitoj količini, učinkovit za supresiju rasta tumora do razmjera koji je najmanje 2 puta od promatranog za nemodificirani agens protiv raka, koji je primijenjen na sličan način tijekom 60 dana.
—C(═O)—N(RD3)(RD4) (wherein RD1, RD2, RD3, RD4, Y, substituent group C and substituent group D are same as those of item 1). 
-C(S0)-NRYR"9, (gdje R"', R*, R'*, R'", Y, supstituentska skupina C, i supstituentska skupina D imaju isto značenje kao što su navedeni u zahtjevu 1).
the maintaining of step (b) is carried out with stirring; and/or 
(111) korak održavanja (b) je izveden miješanjem; i/ili
Method of increasing the transfection efficiency of a cell expressing a membrane or secreted protein of interest in a cell comprising 
Postupak povećanja učinkovitosti transfekcije stanične ekspresije membranskog ili sekrecijskog korisnog proteina u stanici, naznačen time, da, obuhvaća:
The term “IL-18 binding protein” is used herein synonymously with “IL-18BP”. 
Pojam »vezni protein IL-18» ovdje se koristi kao sinonim s «IL-18BP».
The intermediate 1-benzyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole was prepared using the following procedure. 
Intermedijerni 1-benzil-3-(2H-tetrazol-5-il)-1,4,5,6-tetrahidro-ciklopentapirazol je bio pripremljen uporabom slijedećeg postupka:
A pharmaceutical composition comprising a compound of claim 29, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak, naznačen time, da sadrži spoj iz bilo kojeg od patentnih zahtjeva 1-22 ili stereoizomer, farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipijens.
reacting 3-benzy]-6-bromo-2-methoxyquinoline with lithium-diisopropylamide and (3-dimethylamino)-1'-propionaphthone in a suitable solvent, followed by adding a suitable acid; 
reakcije 3-benzil-6-bromo-2-metoksikinolina sa litijevim-diizopropilamidom i (3-dimetilamino)-1'-propionaftonom u pogodnom otapalu, nakon čega slijedi dodavanje pogodne kiseline;
Buprenorphine is a potent, partial agonist of the µ-opioid receptor that has been shown to be effective to control pain in a wide range of patients when delivered by a number of different routes of administration, including intravenously, epidurally, intrathecally, or sublingually in both young and elderly patients (Inagaki et al., Anesth Analg 1996, 83:530-536; Brema et al., Int J Clin Pharmacol Res 1996, 16:109-116; Capogna et al., Anaesthesia 1988, 43:128-130; Adrianensen et al., Acta Anaesthesiol Belg 1985, 36:33-40; Tauzin-Fin et al., Eur J Anaesthesiol 1998, 15:147-152; Nasar et al., Curr Med Res Opin 1986, 10:251-255). 
Buprenorfin je snažan, parcijalni agonist u-opioidnog receptora, za koji se pokazalo da je učinkovit u suzbijanju boli kod široke lepeze pacijenata kada se daje brojnim različitim putevima davanja, uključujući intravenozno, epiduralno, intratekalno ili sublingvalno, i kod mladih i kod starijih pacijenata (Inagaki et al., Anesth Analg 1996, 83:530-536; Brema et al., Int J Clin Pharmacol Res 1996, 16:109-116; Capogna et al., Anaesthesia 1988, 43:128-130; Adrianensen et al., Acta Anaesthesiol Belg 1985, 36:33-40; Tauzin-Fin et al., Eur J Anaesthesiol 1998, 15:147-152; Nasar et al., Curr Med Res Opin 1986, 10:251-255).
CR2 or N; with the proviso that one or two of the variables B, G, D and E must be N; 
E je CR' ili N; pod uvjetom da jedna ili dvije od varijabli B, G, D i E mora biti N;
It is preferred to provide stirring under heating and surcharge the solvent in order to avoid losses of evaporation. 
Poželjno je da se omogući miješanje uz zagrijavanje i da se prezasiti otapalo kako bi se izbjegao gubitak putem isparavanja.
The final pellet is homogenized (20 sec) in this assay buffer (0.5 mg original tissue/well). 
Konačni pellet se homogenizira (20 sek) u tom ispitnom buferu (0.5 mg izvornog tkiva/well).
Herein disclosed is a process for the preparation of a compound of formula VIII wherein PLG is a protecting-leaving group, and Z is hydroxyethyl or a group convertible to hydroxyethyl, the process comprising the steps of: providing a compound of formula VII wherein PLG is defined as above, and 
(1) - pripravljanje spoja formule VII gdje je PLG isti kao što je gore definiran, i (ii) O-alkilacija spoja formule VII u svrhu dobivanja spoja formule VIII, 20
each R1 is, independently, C1-4 alkyl; or two R1 groups form a 2-carbon bridge; 
svaka R1 je, nezavisno, C1-4 alkil; ili dvije R1 grupe formiraju dvočlani ugljikov most;
A drug delivery device comprising a dry powder inhaler containing a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline dioxalate salt of claim 1 . 
Uređaj za davanje lijeka koji sadrži inalator sa suhim prahom koji sadrži sastav prema zahtjevu 7.
The compound according to claim 10, wherein the disease that is generated secondarily as a result of behavior accompanied by itch is cataract, retinal detachment, inflammation, infection or sleeping disorder. 
Spoj u skladu s patentnim zahtjevom 10, naznačen time što je bolest koja je sekundarna posljedica ponašanja praćenog svrbežom katarakta, odvajanje mrežnice, upala, infekcija ili poremećaj spavanja.
multiple sclerosis; 
- multipla skleroza;
Animals are divided into two groups, one group (n=8) fed with the SFA-CHO diet and treated with placebo and one group (n=8) fed with the SFA-CHO diet and treated with the compound (3.0 mg kg−1). 
Životinje su podijeljene u dvije skupine, jedna skupina (n=8) je hranjena sa SFA-CHO dijetom i tretirana sa placebom, a druga skupina (n=8) je hranjena sa SFA-CHO dijetom i tretirana sa spojem (3.0 mg kg") .
a CDRH2 amino acid sequence of SEQ ID NO:20; and a CDRH3 amino acid sequence of SEQ ID NO:44 optionally wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof. 
CDRH2 sekvencu amino kiseline SEK ID BR: 20; i CDRH3 sekvencu amino kiseline SEK ID BR: 44 pri čemu je, opcionalno, spomenuta stanica domaćina najmanje jedna izabrana od COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, HepG2, 653, SP2/0, 293, HeLa, mijeloma, ili stanica limfoma, ili bilo kojeg njihovog derivata, imortalizirane ili transformirane stanice.
The antivirally effective amount of a (2' R)-2'-deoxy-2'-fluoro-2'- C -methyl nucleoside (B-D or B-L) or its pharmaceutically acceptable salt of claim 1, wherein R7 is H and R1 is a monophosphate, a diphosphate, or a triphosphate. 
(2'R)-2'-deoksi-2'-fluoro-2'-C-metil nukleozid (B-D ili B-L) iz patentnog zahtjeva 1 ili njegova farmaceutski prihvatljiva sol, u kojima R7 je H i R1 je monofosfat, difosfat, ili trifosfat.